Chiome Bioscience (TSE:4583) Accounts Payable: 円51.3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4583 Chiome Bioscience Inc TSE:4583
50 GF Score
Price 円97.00
GF Value 円87.77
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Chiome Bioscience Accounts Payable?

Chiome Bioscience TSE:4583 -2.02% 50 Accounts Payable is 円51.3 Mil as of Jun. 2026. GuruFocus rates TSE:4583 with a GF Score™ of 50/100 and a GF Value™ of 円87.77 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Chiome Bioscience's Accounts Payable for the quarter that ended in Jun. 2026 was 円51.3 Mil.

Chiome Bioscience's quarterly Accounts Payable declined from Dec. 2025 (円37.4 Mil) to Mar. 2026 (円34.7 Mil) but then increased from Mar. 2026 (円34.7 Mil) to Jun. 2026 (円51.3 Mil).

Chiome Bioscience's annual Accounts Payable declined from Dec. 2023 (円37.7 Mil) to Dec. 2024 (円27.2 Mil) but then increased from Dec. 2024 (円27.2 Mil) to Dec. 2025 (円37.4 Mil).

Chiome Bioscience Accounts Payable Related Terms

Chiome Bioscience Accounts Payable Historical Data

* Premium members only.

The historical data trend for Chiome Bioscience's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chiome Bioscience Accounts Payable Chart

Chiome Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.81 31.87 37.74 27.20 37.44

Chiome Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.83 35.22 37.44 34.74 51.26
TSE:4583
50GF Score
Chiome Bioscience Inc TSE:4583
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chiome Bioscience Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of 円51.3 Mil mean?
Chiome Bioscience (TSE:4583) has a Accounts Payable of 円51.3 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Chiome Bioscience and its competitors.
Is Chiome Bioscience's Accounts Payable too high?
Chiome Bioscience's current Accounts Payable is 円51.3 Mil. Overall, Chiome Bioscience has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Accounts Payable compare to VRTX and REGN?
Chiome Bioscience's Accounts Payable of 円51.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Chiome Bioscience and its competitors. Chiome Bioscience's current Accounts Payable is 円51.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Modestly Overvalued. The stock's GF Value™ is 円87.77, compared to a current price of 円97.00 — trading 10.5% above its estimated fair value. The current Accounts Payable is 円51.3 Mil. Chiome Bioscience's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Accounts Payable is 円51.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chiome Bioscience (TSE:4583) Overvalued in 2026?

Based on GuruFocus' analysis, Chiome Bioscience stock appears to be overvalued. The current stock price of 円97.00 is trading 10.5% above its estimated GF Value™ of 円87.77. GuruFocus considers Chiome Bioscience to be Modestly Overvalued.

Key valuation signals for TSE:4583:

  • Accounts Payable: 円51.3 Mil
  • GF Value™: 円87.77 vs. price of 円97.00 (10.5% above fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chiome Bioscience Business Description

Address 3-12-1 Honmachi, No. 6, Sumitomo Fudosan Nishi Shinjuku Building, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
50GF Score

Get the complete analysis for TSE:4583

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円97.00
Price
円87.77
GF Value